Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Orbital metastases from malignant mesothelioma.
Mian I, Padiernos E, Hassan R, Ghafoor A. Mian I, et al. Among authors: hassan r. Lancet Oncol. 2020 Feb;21(2):e117. doi: 10.1016/S1470-2045(19)30822-8. Lancet Oncol. 2020. PMID: 32007197 Free PMC article. No abstract available.
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Hassan R, et al. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. doi: 10.1158/1078-0432.CCR-14-0804. Epub 2014 Sep 17. Clin Cancer Res. 2014. PMID: 25231400 Free PMC article. Clinical Trial.
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA. Gupta A, et al. Among authors: hassan r. Cancer Chemother Pharmacol. 2016 Apr;77(4):733-43. doi: 10.1007/s00280-016-2984-z. Epub 2016 Feb 22. Cancer Chemother Pharmacol. 2016. PMID: 26898299 Free PMC article.
Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R. Khanna S, et al. Among authors: hassan r. J Thorac Oncol. 2016 Nov;11(11):1993-2005. doi: 10.1016/j.jtho.2016.07.033. Epub 2016 Aug 17. J Thorac Oncol. 2016. PMID: 27544053 Free PMC article.
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S, Wang Z, Lasota J, Onda M, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Pastan I, Miettinen M. Inaguma S, et al. Among authors: hassan r. Oncotarget. 2017 Apr 18;8(16):26744-26754. doi: 10.18632/oncotarget.15814. Oncotarget. 2017. PMID: 28460459 Free PMC article.
1,198 results